Systemic therapy for advanced hepatocellular carcinoma: a review.
about
Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study.Current systemic treatment of hepatocellular carcinoma: A review of the literatureQuercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xlSystemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma.Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies.Matrine induces caspase-independent program cell death in hepatocellular carcinoma through bid-mediated nuclear translocation of apoptosis inducing factorOncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.Complete response for advanced liver cancer during sorafenib therapy: case report.14-3-3ε boosts bleomycin-induced DNA damage response by inhibiting the drug-resistant activity of MVPSystemic treatment of hepatocellular carcinoma: Past, present and futureInhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin.Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis.Targeting and eradicating hepatic cancer cells with a cancer-specific vector carrying the Buforin II geneCisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era.Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Obstructive jaundice caused by hepatocellular carcinoma with bile duct tumor thrombi: a case report.Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosisCombination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis.Fucoidan induces apoptosis of HepG2 cells by down-regulating p-Stat3.Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinomaβ-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.The Limonoids TS3 and Rubescin E Induce Apoptosis in Human Hepatoma Cell Lines and Interfere with NF-κB SignalingActivity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.Hepatocellular carcinoma masquerading as a bleeding gastric ulcer: a case report and a review of the surgical management.Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.Resveratrol-loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles wrapping resveratrol nanoparticles: Preparation, characterization, and targeting effect on liver tumors.Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.SSX2IP promotes metastasis and chemotherapeutic resistance of hepatocellular carcinomaPreparation of 10-hydroxycamptothecin-loaded glycyrrhizic acid-conjugated bovine serum albumin nanoparticles for hepatocellular carcinoma-targeted drug deliveryInterferon-α sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-κB activationEffective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model.Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study.Low-dose chemotherapy of hepatocellular carcinoma through triggered-release from bilayer-decorated magnetoliposomes.Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis.Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever.NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin.Enhancement of antitumor activity of low-dose 5-fluorouracil by combination with Fuzheng-Yiliu granules in hepatoma 22 tumor-bearing mice.Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas.Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells
P2860
Q25257445-EC4E11B5-2806-47DB-A5A5-D014A847C05BQ27026036-8EB9DBB7-2F90-4FA4-B79A-747592475181Q28484294-07CBD57D-57BD-4640-B0C8-851E95641614Q33400353-3ACEA865-58B1-49F7-BEB1-28A761A363B2Q33414726-EBC95A31-420A-4683-AF49-41E07E096491Q33556739-56C1E46C-F34B-4744-9BE6-92BB9CB4900AQ33635033-961194A5-42C3-4890-BDE3-DCBFDFD1BEA8Q33795187-20ECD9A6-B0F4-4493-A42D-F2FD31DEB601Q33828898-70C2EB5C-4D41-46B6-A28E-B69041C1E25EQ33854034-3778B11D-CDA2-41A5-91EB-053FE5966F63Q33866286-64DA8C07-9636-4E50-B3C1-E626938D5E2EQ33920344-789E8291-D75F-4B77-8932-ED71E8B024B2Q34404821-CE31A107-2A72-4A4E-9985-B270CCA40B96Q34494749-12E119C3-4610-4A28-92F6-E322368C0A52Q34632966-F247C2CF-AD8D-42CF-971E-76CDB834523EQ34666306-04626A45-69FF-4DEA-ABDD-F527AA541198Q35122619-5AC956E8-04FA-4AA0-9813-7013D854B750Q35180039-5ADD1E93-B6F1-4FCF-8C4C-0D2C190F9F97Q35190023-3E53BB5E-C085-422D-AF9D-5830EE091A9EQ35263043-36CD3024-3BCC-4556-8CEA-E13B45C6E874Q35921211-703951CE-0718-49F4-99EA-C89AE38759A7Q36102767-9D7693E2-3425-40FF-8CF5-0B0105B4A629Q36178201-9917C876-85E8-4CB7-BD3B-745D6D9604F6Q36179115-83D99E1C-A111-4FCC-A0BA-E717FB8EDBB3Q36181200-54B19544-4AC4-45CE-AEA8-7E6517EA871EQ36184640-A1BCE2DF-7C3C-491A-9762-4243BDFD47FCQ36404559-53DDBF47-6163-4DCB-9963-5220B40CC155Q36611050-DF66A4AB-A1B6-4C23-B14C-5ECACC932330Q36691348-FD03C947-3B77-4828-9E2A-453FAF1F882AQ36738734-1723AD1E-BB72-4A45-920C-17D73C56292AQ36922267-EFDD9125-72F1-4287-9810-08E085DFD989Q37286152-44B99F4D-7E8B-4F6C-88C7-25C7EB1B749DQ37475722-C62943EC-E217-4F35-9817-FAB823D6526CQ37716938-C444C2AD-9DFE-4D5E-9C5A-468EA5DCFCB3Q37722175-C9EE8F70-F348-4AAB-B3B7-97ACDF080387Q38176402-AFB1F797-6318-4D4E-869E-2020B61B01BBQ39180778-B17B43B5-FDDF-4E8E-9953-0DB2C08FD0FEQ39315439-ADCF5DEA-ACF4-4AA0-8FC0-F45DA7186AF6Q39488089-B6576F35-BA36-44E0-96D6-A08CDCBDABE3Q39569578-3C7C7FD5-EDFD-44E6-8A22-0F36BA42EA2C
P2860
Systemic therapy for advanced hepatocellular carcinoma: a review.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Systemic therapy for advanced hepatocellular carcinoma: a review.
@ast
Systemic therapy for advanced hepatocellular carcinoma: a review.
@en
type
label
Systemic therapy for advanced hepatocellular carcinoma: a review.
@ast
Systemic therapy for advanced hepatocellular carcinoma: a review.
@en
prefLabel
Systemic therapy for advanced hepatocellular carcinoma: a review.
@ast
Systemic therapy for advanced hepatocellular carcinoma: a review.
@en
P1476
Systemic therapy for advanced hepatocellular carcinoma: a review
@en
P2093
Michael Findlay
P304
P356
10.1016/J.EJCA.2004.02.027
P577
2004-07-01T00:00:00Z